Bayer AG (BAYN)
BAYN · Health Care · 
Germany
Bayer AG (BAYN) is a German company in the Health Care sector. The stock has its largest weight in EXS1 (DAX), at 2.64%. Anyone who holds an ETF containing Bayer also has an indirect stake in the company.
Data and Charts: Bayer
Key Data for Bayer
Alysly Data Analysis: Bayer
Bayer Connections
The map shows how Bayer connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- Germany Country · domicile
- Health Care Sector · sector
- Fresenius Medical Care Stock · similar ETF exposure
- Fresenius Stock · similar ETF exposure
What ETF Is Bayer In?
Bayer has very high ETF coverage and is held by 34 of the 104 ETFs we track, which together follow 13 indices. That puts the stock in more ETFs than 99.9% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| EXS1 | DAX | 2.64% | €26.40 |
| DBXD / XDDA | DAX | 2.64% | €26.39 |
| XESC / XESX | Euro STOXX 50 | 1.06% | €10.62 |
| ZPRE | MSCI EMU | 0.73% | €7.25 |
| XD5E | MSCI EMU | 0.72% | €7.21 |
| XEMU | MSCI EMU | 0.72% | €7.21 |
| XDWH | MSCI World Health Care | 0.58% | €5.80 |
| SPFS | MSCI World Health Care | 0.58% | €5.79 |
| XDEV | MSCI World Value | 0.48% | €4.76 |
| SPYE | MSCI Europe | 0.38% | €3.81 |
| XMEU / XIEE | MSCI Europe | 0.38% | €3.81 |
| IMEA | MSCI Europe | 0.38% | €3.80 |
| EXSA | STOXX Europe 600 | 0.35% | €3.50 |
| XSX6 / XSX7 | STOXX Europe 600 | 0.35% | €3.49 |
| X600 / XESU | STOXX Europe 600 | 0.35% | €3.49 |
| WVAL | MSCI World Value | 0.27% | €2.71 |
| EXUS / EXU1 | MSCI World ex USA | 0.21% | €2.14 |
| XDEM | MSCI World Momentum | 0.17% | €1.69 |
| SPYI / SPSA | MSCI ACWI IMI | 0.08% | €0.84 |
| EUNL | MSCI World | 0.06% | €0.60 |
| XDWD / XDWL | MSCI World | 0.06% | €0.58 |
| SWWD | MSCI World | 0.06% | €0.57 |
| SPPW | MSCI World | 0.06% | €0.57 |
| WIMI | MSCI World IMI | 0.05% | €0.52 |
| SPYY | MSCI ACWI | 0.05% | €0.51 |
| IUSQ | MSCI ACWI | 0.05% | €0.50 |
The last column shows how much of €1,000 in one of these funds goes to Bayer, based on each fund's latest holdings list.
US-listed ETFs holding Bayer (weight per latest SEC filing): VXUS 0.12%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Bayer Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Bayer had a weight of 0.16% on Sep 30, 2019 and 0.06% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.17% on Dec 31, 2019. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Bayer overlaps with the rest of a portfolio.
Stocks With ETF Exposure Similar to Bayer
| Stock | Shared ETFs | r |
|---|---|---|
| Bayer | – | – |
| Fresenius Medical Care | 31 | – |
 Fresenius | 31 | – |
| Qiagen | 31 | – |
 Siemens Healthineers | 30 | – |
 DHL N | 32 | – |
 Bayerische Motoren Werke | 31 | – |
 Mercedes-Benz Group N | 31 | – |
| Deutsche Bank Aktiengesellschaft | 31 | – |
These stocks reach a portfolio through largely the same funds as Bayer. “Shared ETFs” counts the funds that hold both.
Fundamental Analysis: Bayer
Latest Patents Granted to Bayer
In the 52 weekly issues of the US patent office from Nov 4, 2025 to Oct 27, 2026, Bayer received 92 utility patents and 1 design patents. That is 0.029% of all utility patents the US patent office granted in those weeks. The median time from filing to grant was 5.0 years.
| Granted | Patent | Title | Filed | Technology field |
|---|---|---|---|---|
| US 12774273 B2 | Substituted thiophene carboxamides and derivatives thereof | C07D Chemistry; metallurgy | ||
| US 12770726 B2 | System, method, and computer program product for providing a gateway to connect a fluid delivery system and external systems | G16H Healthcare informatics | ||
| US 12760047 B2 | Phosphorus derivatives as SOS1 inhibitors | C07F Chemistry; metallurgy | ||
| US 12759981 B2 | Cholinate of 2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[([{1-[2-fluoro-4-(trifluoromethyl)-phenyl]cyclopropyl}carbonyl)amino]benzoic acid | C07D Chemistry; metallurgy | ||
| US 12746330 B2 | Fluid paths for angiography injector assembly | A61M Human necessities |
These are grants, not applications. The office usually publishes an application 18 months after the priority date; the grant tends to come much later. Owners counted: BAYER AKTIENGESELLSCHAFT; BAYER HEALTHCARE LLC; Bayer Pharma Aktiengesellschaft and Bayer Oy. Titles as published by the office; median time based on 41 patents with a known filing date.
The patent screener lists more grants, filterable by company, type and technology field. The M&A and patents page compares companies.
